Search research articles
Contact Us
Filters
Showing results (581-590 of 661) with videos related to
Page
of 67
Sort By:
The Lancet. Respiratory Medicine
|
May 8, 2023
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Shun Lu, Lin Wu, Hong Jian, et al.
Cancer Cell
|
August 13, 2021
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
Qing Zhou, Chong-Rui Xu, Ying Cheng, et al.
Future Oncology (London, England)
|
November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
Yi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Solange Peters, Luis G Paz-Ares, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 2, 2025
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study
Yi-Long Wu, Hye Ryun Kim, Ross A Soo, et al.
The Lancet. Oncology
|
July 31, 2022
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Shun Lu, Lin Wu, Hong Jian, et al.
The Journal of Clinical Investigation
|
May 25, 2011
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Markus Gödel, Björn Hartleben, Nadja Herbach, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
Hidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
Genome Medicine
|
January 10, 2023
Single-cell transcriptomics reveals a mechanosensitive injury signaling pathway in early diabetic nephropathy
Shuya Liu, Yu Zhao, Shun Lu, et al.
JTO Clinical and Research Reports
|
May 24, 2023
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced <i>ALK</i>-Positive NSCLC
Qing Zhou, Ross A Soo, Gee-Chen Chang, et al.
Page
of 67
Search research articles
Search
Showing results (581-590 of 661) with videos related to
Sort By:
Page
of 67
The Lancet. Respiratory Medicine
|
May 8, 2023
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Shun Lu, Lin Wu, Hong Jian, et al.
Cancer Cell
|
August 13, 2021
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
Qing Zhou, Chong-Rui Xu, Ying Cheng, et al.
Future Oncology (London, England)
|
November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
Yi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Solange Peters, Luis G Paz-Ares, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 2, 2025
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study
Yi-Long Wu, Hye Ryun Kim, Ross A Soo, et al.
The Lancet. Oncology
|
July 31, 2022
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Shun Lu, Lin Wu, Hong Jian, et al.
The Journal of Clinical Investigation
|
May 25, 2011
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Markus Gödel, Björn Hartleben, Nadja Herbach, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
Hidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
Genome Medicine
|
January 10, 2023
Single-cell transcriptomics reveals a mechanosensitive injury signaling pathway in early diabetic nephropathy
Shuya Liu, Yu Zhao, Shun Lu, et al.
JTO Clinical and Research Reports
|
May 24, 2023
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced <i>ALK</i>-Positive NSCLC
Qing Zhou, Ross A Soo, Gee-Chen Chang, et al.
Page
of 67